245 related articles for article (PubMed ID: 25924576)
1. Patent watch: Have the biosimilar floodgates been opened in the United States?
Brinckerhoff CC; Schorr K
Nat Rev Drug Discov; 2015 May; 14(5):303-4. PubMed ID: 25924576
[No Abstract] [Full Text] [Related]
2. Assessing biosimilarity and interchangeability of biosimilar products.
Chow SC
Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
[No Abstract] [Full Text] [Related]
3. Patent watch: post-approval testing shielded from patent infringement.
Harrison C
Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 23097768
[No Abstract] [Full Text] [Related]
4. Strategic considerations under the Biologics Price Competition and Innovation Act.
Marquardt JL; Auten SR
Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
[TBL] [Abstract][Full Text] [Related]
5. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
6. Patent litigation could make 2017 no 'dancing' matter.
Reinke T
Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars in the Caribbean--key considerations.
Cox SD
West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
[No Abstract] [Full Text] [Related]
8. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
9. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
10. Biosimilar Makers Hope Court Starts 6-Month Wait Sooner.
Silverman E
Manag Care; 2017 Mar; 26(3):31. PubMed ID: 28510518
[TBL] [Abstract][Full Text] [Related]
11. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
12. Are biosimilars patentable?
Rolfe D; Parker J; Morgan M
Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars.
Bagel J
J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
[No Abstract] [Full Text] [Related]
14. Biosimilars: how similar?
Strand V; Cronstein B
Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
[TBL] [Abstract][Full Text] [Related]
15. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
16. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
17. A cheat sheet to navigate the complex maze of exclusivities in the United States.
Peng B; Tomas MC
Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
[No Abstract] [Full Text] [Related]
18. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
Bloch DJ
Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
[No Abstract] [Full Text] [Related]
19. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
20. FDA sets hierarchy for biosimilars evidence.
Ratner M
Nat Biotechnol; 2014 Jul; 32(7):609. PubMed ID: 25004221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
